ACC 2024 — Late-breaker host, Dr Harriette Van Spall and Principal Investigator, Dr C Michael Gibson discuss the AEGIS-II trial (CSL Behring) (NCT03473223).

This phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study investigated the efficacy and safety of an apolipoprotein A-I (apoA-I), CSL112 in patients with acute coronary syndrome (ACS). Investigators enrolled 18200 participants. The primary outcome measure is the time to first occurrence of any component of composite MACE.

Findings revealed at ACC.24 showed that amongst acute myocardial infarction patients with multivessel disease and additional cardiovascular risk factors on guideline directed background therapies, four weekly infusions of CSL112 did not significantly reduce cardiovascular death, MI or stroke through 90 days.

Secondary findings showed that that as baseline LDL-C increased, the potential treatment effect of ApoA-I infusion significantly increased when analysed as a continuous variable.

Recorded remotely from Boston and Hamilton, 2024.

For more content from ACC.24 head to the Late-breaking Science Video Collection.

Support: This is an independent content produced by Radcliffe Cardiology.

Editor: Mirjam Boros
Videographer: Tom Green, Mike Knight